Abstract:The (R)-enantiomer of 2-hydroxyglutarate, which is produced when IDH is mutated in human tumours, is shown to stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of HIF and enhanced human astrocyte proliferation. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 have been identified in gliomas, the most common form of brain tumour, and in other cancers including leukaemias. The mutated enzymes produce 2-hydroxyglutarate (2HG), which is a potential oncometabolite. Three papers in this issue of Nature examine the mechanisms through which IDH mutations promote cancers. Lu et al. show that 2HG-producing IDH mutants can prevent the histone demethylation that is required for progenitor cells to differentiate, potentially contributing to tumour-cell accumulation. Turcan et al. show that IDH1 mutation in primary human astrocytes induces DNA hypermethylation and reshapes the methylome to resemble that of the CIMP phenotype, a common feature of gliomas and other solid tumours. Koivunen et al. show that the (R)-enantiomer of 2HG (but not the (S)-enantiomer) can stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of hypoxia-inducible factor (HIF), which in turn can enhance cell proliferation. These papers establish a framework for understanding gliomagenesis and highlight the interplay between genomic and epigenomic changes in human cancers. The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation1. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG)2,3. Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.

R-2-hydroxyglutarate As the Key Effector of IDH Mutations Promoting Oncogenesis.

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

R-2-Hydroxyglutarate Induces RIPK1-Dependent Necroptosis Via Inhibition of KDM2B in Myeloid Malignancies

The Mechanisms of IDH Mutations in Tumorigenesis

Isocitrate Dehydrogenase 2 Mutations Correlate with Leukemic Transformation and Are Predicted by 2-Hydroxyglutarate in Myelodysplastic Syndromes

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

Metabolism, Activity, and Targeting of D-and L-2-Hydroxyglutarates

D-2-hydroxyglutarate is Essential for Maintaining Oncogenic Property of Mutant IDH-containing Cancer Cells but Dispensable for Cell Growth

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability

Oncometabolite 2-Hydroxyglutarate is a Competitive Inhibitor of Α-Ketoglutarate-dependent Dioxygenases

IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities.

P86.21 Activating IDH Mutation As Resistance Mechanism to EGFR TKI in EGFR+ NSCLC

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Lysine Acetylation Restricts Mutant IDH2 Activity to Optimize Transformation in AML Cells.

Comprehensive Exploration of Isocitrate Dehydrogenase (IDH) Mutations: Tumorigenesis, Drug Discovery, and Covalent Inhibitor Advances

2-Hydroxyglutarate Production, but Not Dominant Negative Function, is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway